{"nctId":"NCT01212484","briefTitle":"Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia","startDateStruct":{"date":"2009-12"},"conditions":["Familial Dysautonomia"],"count":12,"armGroups":[{"label":"Placebo (first), Carbidopa (second)","type":"EXPERIMENTAL","interventionNames":["Drug: Carbidopa","Drug: Placebo"]},{"label":"Carbidopa (first), Placebo (second)","type":"EXPERIMENTAL","interventionNames":["Drug: Carbidopa","Drug: Placebo"]}],"interventions":[{"name":"Carbidopa","otherNames":["Lodosyn"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male of female patients aged 12 and older\n* Confirmed diagnosis of familial dysautonomia by genetic testing.\n* Symptoms of severe nausea\n* Written informed consent or ascent to participate in the pilot trial and understanding that they can withdraw consent at anytime without affecting their future care.\n* Ability to comply with the requirements of the study procedures, including taking blood pressure measurements at home.\n\nExclusion Criteria:\n\n* Patients taking metroclopromide, domperidone, risperidone or other dopamine blockers\n* Patients taking MAO-inhibitors\n* Patients taking tricyclic antidepressants\n* Patients taking neuroleptic drugs (haloperidol and chlorpromazine)\n* Patients with a known hypersensitivity to any component of this drug.\n* Patients with atrial fibrillation, angina or an electrocardiogram documenting significant abnormality that may jeopardize the patient's health.\n* Patients with significant pulmonary, liver, renal (creatinine \\>2.0 mg/ml) or cardiac illness\n* Patients who are unable to clearly identify and rate their symptoms of nausea.\n* Women who are pregnant or lactating\n* Patients who have a significant abnormality on clinical examination that may, in","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Composite Daily Score","description":"Daily scores were reported on a modified version of the Rhodes Index of Nausea, Vomiting and Retching, which included all 5 items relating to nausea and retching. Items addressing vomiting/throwing up were omitted, as all participants had antireflux surgery that prevented vomiting (Nissen fundoplication). Retching distress, nausea distress, number of nausea episodes per day, number of retching episodes per day, and the amount of time spent feeling nauseous were graded on a 5-point scale. Scores range from 0 (no nausea/distress) to 20 (most nausea/distress).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"2.2"},{"groupId":"OG001","value":"9.7","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Number of Episodes of Daily Nausea","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.8"},{"groupId":"OG001","value":"2.0","spread":"1.0"}]}]}]},{"type":"PRIMARY","title":"24 Hour Dopamine Levels","description":"Assay of 24 hour dopamine level excretion in urine","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":"29"},{"groupId":"OG001","value":"222","spread":"41"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":12},"commonTop":[]}}}